Literature DB >> 3071068

Miscibility of semisynthetic human ultralente insulin with short-acting insulin in insulin-dependent diabetic patients.

M Lunetta1, M di Mauro, S Crimi, L Sudano, L Mughini.   

Abstract

In 15 insulin dependent diabetics (IDDM), treated with human monocomponent insulin, the absorption of Actrapid HM mixed with Ultratard HM was evaluated. Thirty U of Ultratard HM and 10 U of Actrapid HM were injected separately or together immediately after mixing. Free insulin and plasma glucose (PG) were measured four hours after the administration. Free insulin levels were significantly higher after 15 (2p less than 0.01), 60 (2p less than 0.05) and 90 min (2p less than 0.005) when the two insulins were injected separately. PG values were significantly lower (2p less than 0.05) (7.63 +/- 4.06 mmol/l) at 120 min when the two insulins were injected separately compared to the mixture (9.45 +/- 4.22 mmol/l). In conclusion, mixing Ultratard HM and Actrapid HM 3:1, we observed a decrease of early Actrapid absorption and a slower lowering of PG values.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3071068     DOI: 10.1007/bf02624822

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  10 in total

1.  Miscibility of human lente insulin with soluble insulin.

Authors:  M Tsotsalas; I Mühlhauser
Journal:  Diabetologia       Date:  1985-04       Impact factor: 10.122

2.  Miscibility of human and bovine ultralente insulin with soluble insulin.

Authors:  I Mühlhauser; C Broermann; M Tsotsalas; M Berger
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-15

3.  Type I diabetes . . . regimens, targets, and caveats.

Authors:  J S Skyler
Journal:  Diabetes Care       Date:  1982 Sep-Oct       Impact factor: 19.112

4.  Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures.

Authors:  J A Galloway; C T Spradlin; R L Nelson; S M Wentworth; J A Davidson; J L Swarner
Journal:  Diabetes Care       Date:  1981 May-Jun       Impact factor: 19.112

5.  Human ultralente insulin.

Authors:  R R Holman; J Steemson; P Darling; W G Reeves; R C Turner
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-03

6.  Intermediate-acting insulin preparations: NPH and lente.

Authors:  T Deckert
Journal:  Diabetes Care       Date:  1980 Sep-Oct       Impact factor: 19.112

7.  Absorption kinetics of semisynthetic human insulin and biosynthetic (recombinant DNA) human insulin.

Authors:  F W Kemmer; G Sonnenberg; H J Cüppers; M Berger
Journal:  Diabetes Care       Date:  1982 Nov-Dec       Impact factor: 19.112

8.  Absorption kinetics and biologic effects of subcutaneously injected insulin preparations.

Authors:  M Berger; H J Cüppers; H Hegner; V Jörgens; P Berchtold
Journal:  Diabetes Care       Date:  1982 Mar-Apr       Impact factor: 19.112

9.  The effect of mixing human soluble and human crystalline zinc-suspension insulin: plasma insulin and blood glucose profiles after subcutaneous injection.

Authors:  A J Francis; I Hanning; K G Alberti
Journal:  Diabet Med       Date:  1985-05       Impact factor: 4.359

10.  Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins.

Authors:  R J Heine; H J Bilo; T Fonk; E A van der Veen; J van der Meer
Journal:  Diabetologia       Date:  1984-12       Impact factor: 10.122

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.